Acyclovir Dosing for Cold Sores (Herpes Labialis)
For immunocompetent adults with recurrent cold sores, use acyclovir 800 mg orally twice daily for 5 days, initiated during prodrome or within 2 days of lesion onset. 1
Standard Treatment Regimens for Adults
The CDC provides three equally effective oral acyclovir options for recurrent herpes labialis, all for 5 days: 1
- Acyclovir 800 mg twice daily (preferred for convenience and adherence)
- Acyclovir 400 mg three times daily 1, 2
- Acyclovir 200 mg five times daily 3, 1
The 800 mg twice-daily regimen demonstrates superior clinical outcomes with shorter symptom duration (8.1 vs 12.5 days with placebo, p=0.02), reduced pain duration (2.5 vs 3.9 days, p=0.02), and fewer lesions developing (7% vs 26%). 1
Critical Timing Considerations
Treatment must be initiated during the prodrome or within 2 days of lesion onset for maximum benefit. 1 Starting therapy after this window significantly reduces effectiveness, and most immunocompetent patients with recurrent disease experience limited benefit from delayed therapy. 1 This narrow therapeutic window is the single most important factor determining treatment success.
Pediatric Dosing
For children with oral HSV infection: 2
- Children < 45 kg: Acyclovir 20 mg/kg orally three times daily (maximum 400 mg/dose) for 5-10 days
- Severe gingivostomatitis requiring hospitalization: Start IV acyclovir 5-10 mg/kg every 8 hours, then transition to oral therapy once lesions regress 2
Renal Impairment Adjustments
While the provided guidelines do not specify exact renal dosing for oral herpes, acyclovir is primarily renally excreted and requires dose adjustment in renal insufficiency. 2 Standard practice involves reducing frequency based on creatinine clearance, though specific adjustments should follow manufacturer guidance.
Alternative Antiviral Options
For patients seeking more convenient regimens: 1
- Valacyclovir 2 g twice daily for 1 day (comparable efficacy with superior convenience)
- Famciclovir 1500 mg single dose (significantly reduces healing time: 4.4 vs 6.2 days with placebo, p<0.001)
These alternatives offer improved adherence through simplified dosing while maintaining equivalent or superior efficacy.
Suppressive Therapy for Frequent Recurrences
For patients with ≥6 episodes per year, daily suppressive therapy reduces recurrence frequency by ≥75%: 2
- Acyclovir 400 mg orally twice daily (continuous suppression)
- Safety documented for up to 6 years of continuous use 3
- After 1 year, discuss discontinuation to reassess recurrence rate 3
Suppressive therapy reduces but does not eliminate asymptomatic viral shedding, so transmission prevention remains uncertain. 3
Severe or Complicated Disease
For severe disease requiring hospitalization (disseminated infection, immunocompromised patients with extensive involvement): 3, 2
- IV acyclovir 5-10 mg/kg every 8 hours for 5-7 days or until clinical resolution
- Transition to oral therapy once improvement occurs 2
Important Clinical Caveats
Oral acyclovir is significantly more effective than topical formulations for cold sores. 1 Topical acyclovir shows minimal benefit, shortening lesion duration by only about one day. 4, 5
Acyclovir neither eradicates latent virus nor affects subsequent risk, frequency, or severity of recurrences after discontinuation. 1 Patients must understand this is suppressive, not curative therapy.
Patients should abstain from activities that might spread the virus while lesions are present, though transmission can occur during asymptomatic periods. 1
Acyclovir-Resistant HSV
For immunocompromised patients with lesions unresponsive to acyclovir: 2
- Foscarnet 40 mg/kg IV three times daily or 60 mg/kg IV twice daily
- Resistance occurs predominantly in immunocompromised populations 6
Immunocompromised Patients
Higher doses may be required for immunosuppressed patients: 2